Abpro

We're a public biotech company (Nasdaq: ABP) leveraging our proprietary DiversImmune® and MultiMab platforms to advance next-generation antibody therapeutics for immuno-oncology and ophthalmology. Collaborating with global pharmaceutical and research partners, we're advancing a robust pipeline of innovative treatments. For more information, please visit https://abpro.co/